Effect of COV2 vaccine formulation on the ability to generate antibodies against coronavirus

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523712-37-00

Acronym

COV2FIN12

Enrollment

Registered

2025-12-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Booster immunisation against COVID-19 disease caused by SARS-COV-2 Virus

None listed

Sex/Gender

All

Age

18 Years to No maximum

Finland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026